Malaria Vaccines Market 2020 Global Size, Share, Emerging Trends, Company Profiles with Growth Factors by Forecast 2026

Malaria is a severe and widespread disease caused by a parasitic infection by protozoan Plasmodium when transmitted by various species of anopheles mosquitoes. In 2009, according to WHO, 214 Mn to 397 Mn clinical malaria cases were reported worldwide. However, high estimates of around 515 Mn clinical cases of P. falciparum were projected in 2002. Furthermore, malaria accounted for around 3% of the world's total Disability Adjusted Life Years (DALYs) lost and around 10% in Africa alone.

According to Centers for Disease Control and Prevention (CDC), there are around 156 types of Plasmodium species that infect various species of vertebrates. Among the numerous plasmodium species, four are considered true parasites of humans, as they utilize humans almost exclusively as a natural intermediate host: P. falciparum, P. vivax, P. ovale and P. malariae. Over 85% of malaria mortality is due to P. falciparum. Around 90% of deaths caused by malaria in Sub-Saharan Africa is primarily due to P. falciparum.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/37

Market Dynamics

The growing incidence of malaria globally and major players pledging for low profit margin over vaccines is expected to boost growth of the malaria vaccines market. According to World Health Organization (WHO), in 2015, approximately 292,000 children in Africa died of malaria, at very early age of 5 years. Around 306,000 fatalities associated with malaria were reported worldwide in 2015, out of which around 90% cases were reported in Africa.

According to World Health Organization (WHO), first global malaria vaccines has been piloted in the 3 countries of sub-Saharan Africa in April 2019, with the total investment of around US$ 1 Bn. The program is partly funded by the Bill & Melinda Gates Foundation and African Research Centers. The vaccine is being developed by GSK at their lab in Belgium in collaboration with Path, which is an international non-profit organization. This ensures the cost effectiveness of the vaccine though it has taken around 30 years to develop at a cost of US$ 565 Mn. The company pledges not to make a profit from sales of the vaccine and adheres to the price range of around US$ 5 per shot.

Tremendous potential in the malaria vaccines market

Potential for malaria vaccines is estimated to be huge as a large share of population, 90%-95%, at risk of infection in Africa and South East-Asia. Advent of vaccines for adult population, would be a major breakthrough for the malaria vaccines market. Below are certain alarming statistics that embarks the need for a malaria vaccine:

Artemisinin resistance has been detected in five countries - Laos, Cambodia, Myanmar, Vietnam and Thailand
Resistance to P. falciparum parasite against the most available anti-malarial medicines is being reported
According to the National Vector Borne Disease Control Programme, nearly 95% of the population in India reside in malaria endemic areas
There were 216 million malaria cases globally in 2016 (WHO)
Africa is the most affected region with 90% of malaria cases and deaths worldwide (WHO)
Pregnant women, children below 5 years of age, and tourists from countries with low incidence rate of malaria are identified as the most susceptible target population for malaria
The global malaria vaccines market is expected to experience a huge trajectory growth with the launch of first malarial vaccine in near future.

Increasing accessibility and government support to contribute towards the malaria vaccines market growth

The WHO has established a Global Technical Strategy for Malaria 2016-2030 (GTS) in 2015 with certain defined goals, one of them aimed at eliminating malaria in at least 10 countries. Similarly, the Indian government has established Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for providing easy access to anti-malarial drugs. Regular monitoring and surveillance by various government programs has helped to reduce malarial cases in India from 2.03 million in 2010 to 1.1 million in 2015. Support from such national and global initiatives will drive malaria vaccines market growth during the forecast period.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/37

Many such non-profit organizations and pharmaceutical companies are conducting research on malaria vaccines. Approximately 31 trials are under progress for malaria vaccine development with a few being blood stage projects. Availability of funds and government support programs will encourage commercialization of product with successful trial results, thus boosting the malaria vaccines market growth trajectory.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.